| 排名 | 分析师 | 机构 | 行业 | 年度收益率 | 6个月收益率 | 3个月收益率 | 正收益比例 | 成分股数量 | 历史最大跌幅 | 更新日期 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 胡博新 | 华鑫证券 | 医药生物 | 51.17% | 52.55% | 53.72% | -6.32% | 5 | -51.98% | 2025-08-18 |
| 2 | 周豫 | 太平洋 | 医药生物 | 51.11% | 37.92% | 34.66% | 21.21% | 23 | -55.62% | 2025-08-26 |
| 3 | 唐寅灏 | 中信证券 | 医药生物 | 51.03% | 54.42% | 18.54% | 85.71% | 13 | -8.47% | 2025-07-03 |
| 4 | 夏禹 | 国联民生 | 医药生物 | 51.01% | 49.01% | 22.49% | 20.00% | 7 | -52.01% | 2025-08-07 |
| 5 | 年庆功 | 国海证券 | 医药生物 | 50.99% | 53.29% | 41.13% | -25.00% | 7 | -18.14% | 2025-08-22 |
| 6 | 夏禹 | 国联民生 | 医药生物 | 50.96% | 44.77% | 35.04% | 20.00% | 7 | -52.01% | 2025-06-06 |
| 7 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 50.93% | 51.85% | 51.65% | 12.50% | 4 | -27.10% | 2025-04-25 |
| 8 | 唐寅灏 | 中信证券 | 医药生物 | 50.90% | 61.93% | 26.52% | 85.71% | 13 | -8.47% | 2025-07-10 |
| 9 | 夏禹 | 国联民生 | 医药生物 | 50.89% | 48.58% | 25.27% | 20.00% | 7 | -52.01% | 2025-08-12 |
| 10 | 夏禹 | 国联民生 | 医药生物 | 50.84% | 47.30% | 31.28% | 20.00% | 7 | -52.01% | 2025-06-16 |
| 11 | 唐寅灏 | 中信证券 | 医药生物 | 50.81% | 56.52% | 33.60% | 85.71% | 13 | -8.47% | 2025-07-07 |
| 12 | 周豫 | 太平洋 | 医药生物 | 50.77% | 43.56% | 34.51% | 21.21% | 23 | -55.62% | 2025-08-20 |
| 13 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 50.73% | 53.70% | 50.93% | 12.50% | 2 | -27.10% | 2025-04-21 |
| 14 | 韩世通 | 中信证券 | 医药生物 | 50.73% | 44.15% | 34.59% | -2.04% | 6 | -63.25% | 2025-08-20 |
| 15 | 胡博新 | 华鑫证券 | 医药生物 | 50.71% | 52.44% | 48.03% | -6.32% | 4 | -51.98% | 2025-08-04 |
| 16 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 50.69% | 55.04% | 39.12% | 12.50% | 7 | -27.10% | 2025-05-19 |
| 17 | 韩世通 | 中信证券 | 医药生物 | 50.66% | 40.45% | 35.10% | -2.04% | 6 | -63.25% | 2025-08-28 |
| 18 | 赵海春 | 国金证券 | 医药生物 | 50.64% | 55.74% | 58.27% | -25.00% | 2 | -61.07% | 2025-07-23 |
| 19 | 唐寅灏 | 中信证券 | 医药生物 | 50.64% | 13.29% | -17.26% | 85.71% | 2 | -8.47% | 2025-11-24 |
| 20 | 张林晚 | 上海证券 | 医药生物 | 50.64% | 49.11% | 19.73% | -100.00% | 1 | -18.93% | 2025-09-02 |